151. Activation of the Keap1/Nrf2 stress response pathway in autophagic vacuolar myopathies.
- Author
-
Duleh S, Wang X, Komirenko A, and Margeta M
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Autophagy drug effects, Autophagy physiology, Cell Line, Cohort Studies, Female, Humans, Lysosomal Storage Diseases pathology, Male, Mice, Middle Aged, Muscle, Skeletal drug effects, Muscle, Skeletal pathology, Muscular Diseases pathology, Myositis, Inclusion Body metabolism, Myositis, Inclusion Body pathology, Protein Aggregation, Pathological metabolism, Protein Aggregation, Pathological pathology, Signal Transduction drug effects, Young Adult, Kelch-Like ECH-Associated Protein 1 metabolism, Lysosomal Storage Diseases metabolism, Muscle, Skeletal metabolism, Muscular Diseases metabolism, NF-E2-Related Factor 2 metabolism, Sequestosome-1 Protein metabolism
- Abstract
Nrf2 (nuclear factor [erythroid-derived 2]-like 2; the transcriptional master regulator of the antioxidant stress response) is regulated through interaction with its cytoplasmic inhibitor Keap1 (Kelch-like ECH-associated protein 1), which under basal conditions targets Nrf2 for proteasomal degradation. Sequestosome 1 (SQSTM1)/p62-a multifunctional adapter protein that accumulates following autophagy inhibition and can serve as a diagnostic marker for human autophagic vacuolar myopathies (AVMs)-was recently shown to compete with Nrf2 for Keap1 binding, resulting in activation of the Nrf2 pathway. In this study, we used 55 human muscle biopsies divided into five groups [normal control, hydroxychloroquine- or colchicine-treated non-AVM control, hydroxychloroquine- or colchicine-induced toxic AVM, polymyositis, and inclusion body myositis (IBM)] to evaluate whether Keap1-SQSTM1 interaction led to increased Nrf2 signaling in human AVMs. In toxic AVMs and IBM, but not in control muscle groups or polymyositis, Keap1 antibody labeled sarcoplasmic protein aggregates that can be used as an alternate diagnostic marker for both AVM types; these Keap1-positive aggregates were co-labeled with the antibody against SQSTM1 but not with the antibody against autophagosome marker LC3 (microtubule-associated protein 1 light chain 3). In human AVM muscle, sequestration of Keap1 into the SQSTM1-positive protein aggregates was accompanied by an increase in mRNA and protein levels of Nrf2 target genes; similarly, treatment of differentiated C2C12 myotubes with autophagy inhibitor chloroquine led to an increase in the nuclear Nrf2 protein level and an increase in expression of the Nrf2-regulated genes. Taken together, our findings demonstrate that Nrf2 signaling is upregulated in autophagic muscle disorders and raise the possibility that autophagy disruption in skeletal muscle leads to dysregulation of cellular redox homeostasis. more...
- Published
- 2016
- Full Text
- View/download PDF